APA (7th ed.) Citation

Lambert, S., Adili, R., Yalavarthi, P., Rhoads, N., Dahlof, B., White, A., . . . Holinstat, M. (2022). S298: CS585 IS A FIRST-IN-CLASS COMPOUND TARGETING THE IP RECEPTOR FOR PREVENTION OF THROMBOSIS WITHOUT INCREASED RISK OF BLEEDING. Wiley.

Chicago Style (17th ed.) Citation

Lambert, S., R. Adili, P. Yalavarthi, N. Rhoads, B. Dahlof, A. White, N. Bergh, and M. Holinstat. S298: CS585 IS A FIRST-IN-CLASS COMPOUND TARGETING THE IP RECEPTOR FOR PREVENTION OF THROMBOSIS WITHOUT INCREASED RISK OF BLEEDING. Wiley, 2022.

MLA (9th ed.) Citation

Lambert, S., et al. S298: CS585 IS A FIRST-IN-CLASS COMPOUND TARGETING THE IP RECEPTOR FOR PREVENTION OF THROMBOSIS WITHOUT INCREASED RISK OF BLEEDING. Wiley, 2022.